

Clatterbridge Cancer Centre (CCC) Performance in Delivering Research (PID) Q3 2016/17

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
14/SC/1014	156913	JANUS 1: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line	Number Agreed	5	Date Agreed	26/01/2016	08/01/2016	0	Recruitment Finished	Strict eligibility criteria, difficult to meet criteria with this patient group.
14/LO/1490	158617	CHECKMATE 172: A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal	Number Agreed	6	Date Agreed	30/04/2019	25/01/2016	13	Recruitment Finished	Target Achieved
14/LO/1798	161154	NCRN - 3312 - MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer: A Phase III open-label multicenter randomised study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared to chemotherapy in patients with locally advanced	Number Agreed	6	Date Agreed	18/12/2017	29/01/2016	13	Recruitment Finished	Target Achieved
14/SW/0091	150889	NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC: NSCLC M11089 A Phase 3 Veliparib plus Chemotherapy Study in Adv/Met squamous NSCLC	Number Agreed	4	Date Agreed	31/03/2016	12/02/2016	8	Recruitment Finished	Target Achieved
14/SW/1164	165411	HAWK - CANC3672 - D4193C00001	Number Agreed	3	Date Agreed	01/02/2017	31/03/2016	1	Recruitment Finished	Rare patient group. 8 patients pre-screened/approached and 1 recruited. Non entry as follows: 6 consented but screen failed on central pathology review, 1 patient declined.
15/NE/0149	164909	CANC - 3928 - CONDOR	Number Agreed	2	Date Agreed	31/01/2017	31/03/2016	3	Recruitment Finished	Target Achieved
15/SC/0676	186964	ANNOUNCE - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma	Number Agreed	2	Date Agreed	30/08/2019	27/05/2016	2	Recruitment Finished	Target Achieved
13/WM/0421	136884	TARGOVAX: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas	Number Agreed	10	Date Agreed	01/04/2016	02/05/2016	12	Recruitment Finished	Target Achieved

15/EM/0305	172320	CANC - 4278 - GTX-024 in Advanced, AR+ TNBC: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTX-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)	Number Agreed	2	Date Agreed	02/09/2016	12/09/2016	0	Withdrawn By Sponsor	Unable to achieve recruitment target as Sponsor withdrew the study in the UK due to lack of recruitment.
15/EE/0385	187687	NEPTUNE Lung: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non	Number Agreed	4	Date Agreed	24/09/2018	07/09/2016	5	Withdrawn By Host	Target Achieved
14/LO/0135	129217	BAYER 15396: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve subject	Number Agreed	6	Date Agreed	30/07/2021	22/08/2016	5	Recruitment Finished	Study closed as recruitment target achieved nationally.
15/LO/0448	171812	RAINFALL: NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	12	Date Agreed	31/12/2018	18/08/2016	8	Recruitment Finished	Study closed earlier than planned as recruitment target achieved nationally.
15/EE/0013	170877	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with o	Number Agreed	4	Date Agreed	27/05/2016	13/07/2016	8	Recruitment Finished	Target Achieved
13/LO/1277	124209	SPARTAN - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Number Agreed	6	Date Agreed	08/11/2018	21/06/2016	10	Recruitment Finished	Target Achieved
15/LO/0691	174324	Checkmate - 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen fo	Number Agreed	4	Date Agreed	30/05/2016	31/05/2016	23	Recruitment Finished	Target Achieved
14/LO/1426	158013	NCRN - 2960 - Unresected Stage IIIB - IVM1a Melanoma Treated with Talimogene Laherparepvec	Number Agreed	3	Date Agreed	30/11/2016	09/06/2016	5	Recruitment Finished	Target achieved

15/LO/0236	170073	A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	Number Agreed	6	Date Agreed	31/03/2018	13/06/2016	4	Recruitment Finished	8 patients screened, 2 patients declined due to requirement of fresh biopsy, 2 patients were ineligible and 4 patients were recruited. Study involved complex screening procedures and also has a short screening window.
15/NW/0690	177116	MK-3475-054: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group	Number Agreed	3	Date Agreed	01/03/2024	11/10/2016	2	Recruitment Finished	5 patients consented, 3 were ineligible following screening tests and 2 were recruited.
15/LO/0897	171318	WO29637 - MPDL3280A in renal cell: A phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma	Number Agreed	6	Date Agreed	21/10/2016	12/10/2016	13	Recruitment Finished	Target achieved